Potomac, MD, United States of America

Sreenivas Gannavaram

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sreenivas Gannavaram. Retrieved from https://idiyas.com/inventor/sreenivas-gannavaram

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sreenivas Gannavaram and His Vaccine Patent.

Introduction

Sreenivas Gannavaram is an inventor associated with Potomac, Maryland. His patent work includes research into live attenuated Leishmania parasite vaccines designed with enhanced safety characteristics.

Latest Patents

Gannavaram is listed as an inventor on 1 patent: “LIVE ATTENUATED LEISHMANIA PARASITE VACCINES WITH ENHANCED SAFETY CHARACTERISTICS.” The invention concerns vaccine approaches intended to balance immune protection with improved safety.

Career Highlights

The patent identifies Gannavaram’s contribution to research and development in vaccine technology. The listed assignee is the United States of America, as represented by the Secretary of the Department of Health and Human Services.

Collaborations

Gannavaram’s listed coworkers include Hira L. Nakhasi and Ranadhir Dey, reflecting collaborative work on the vaccine invention.

Conclusion

Sreenivas Gannavaram’s patent record highlights his contribution to developing live attenuated Leishmania parasite vaccines with enhanced safety characteristics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…